Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 15;13(7):1379.
doi: 10.3390/v13071379.

First Detection of SARS-CoV-2 B.1.1.7 Variant of Concern in an Asymptomatic Dog in Spain

Sandra Barroso-Arévalo  1   2 , Belén Rivera  1   2 , Lucas Domínguez  1   2 , José M Sánchez-Vizcaíno  1   2
Affiliations
Case Reports

First Detection of SARS-CoV-2 B.1.1.7 Variant of Concern in an Asymptomatic Dog in Spain

Sandra Barroso-Arévalo et al. Viruses. .

Abstract

Natural SARS-CoV-2 infection in pets has been widely documented during the last year. Although the majority of reports suggested that dogs' susceptibility to the infection is low, little is known about viral pathogenicity and transmissibility in the case of variants of concern, such as B.1.1.7 in this species. Here, as part of a large-scale study on SARS-CoV-2 prevalence in pets in Spain, we have detected the B.1.1.7 variant of concern (VOC) in a dog whose owners were infected with SARS-CoV-2. The animal did not present any symptoms, but viral loads were high in the nasal and rectal swabs. In addition, viral isolation was possible from both swabs, demonstrating that the dog was shedding infectious virus. Seroconversion occurred 23 days after the first sampling. This study documents the first detection of B.1.1.7 VOC in a dog in Spain and emphasizes the importance of performing active surveillance and genomic investigation on infected animals.

Keywords: B.1.1.7; SARS-CoV-2; dog; pet; reverse zoonosis; variant of concern.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Pérez-Campos L.M., Hernández-Huerta M.T., Mayoral-Andrade G., Pérez-Campos E.M., Pérez-Campos E. A letter to the editor on “World Health Organization declares global emergency: A review of the 2019 novel Coronavirus (COVID-19)”. Int. J. Surg. 2020;79:163–164. doi: 10.1016/j.ijsu.2020.05.066. - DOI - PMC - PubMed
    1. Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir. Med. 2021;9:e20–e21. doi: 10.1016/S2213-2600(21)00005-9. - DOI - PMC - PubMed
    1. Happi A.N., Ugwu C.A., Happi C.T. Tracking the emergence of new SARS-CoV-2 variants in South Africa. Nat. Med. 2021;27:372–373. doi: 10.1038/s41591-021-01265-1. - DOI - PubMed
    1. Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055. - DOI - PMC - PubMed

Publication types

Substances